News & Events

Early detection of cognitive decline is critical for effective intervention in Alzheimer’s disease and related dementias. Traditional neuropsychological assessments, while useful for diagnosing impairment, are limited in their ability to detect subtle, preclinical changes. Dr. Martin Sliwinski and colleagues propose a novel approach using ultra-brief, mobile cognitive assessments embedded in daily life through ecological momentary assessment (EMA). This method captures high-frequency, real-world data on cognitive performance, enabling the detection of short-term variability and long-term trends. By integrating these assessments with contextual data (e.g., stress, social engagement, physical activity), researchers can model dynamic cognitive processes and identify early signs of decline.

The drug discovery process remains protracted, costly, and inefficient, particularly in the context of neurodegenerative diseases such as Alzheimer's and Huntington's, where therapeutic development has seen limited success. In this keynote, Dr. Jianying Hu presents a comprehensive overview of how artificial intelligence (AI), including classical machine learning and emerging foundation models, is transforming the landscape of drug discovery. She outlines AI-driven strategies across the drug development pipeline—from target identification and molecular generation to disease progression modeling and clinical trial optimization. Highlighted applications include the use of hidden Markov models to construct integrated disease progression models for Huntington’s and Parkinson’s diseases, enabling nuanced patient stratification and improved trial design.

As the global population ages, cognitive decline and social isolation pose significant challenges to independent living and well-being. In this keynote, Dr. Pattie Maes presents a series of innovative research initiatives from the MIT Media Lab’s Fluid Interfaces group that explore how artificial intelligence (AI) and wearable technologies can support healthy aging. Through participatory design workshops with older adults (ages 70–94), her team identified key areas of need, including memory support, communication assistance, health monitoring, and social connection. Prototypes such as MemPal, a wearable memory assistant using multimodal AI to track daily activities and locate lost objects, and a voice-based memory augmentation system were developed and tested in real-world settings. Additional systems include real-time speech simplification tools and AI-enhanced social agents designed to reduce loneliness by promoting and supporting human relationships.

MassAITC hosted the 2025 a2 National Symposium in Boston, MA on April 3-4, 2025. We invite you to watch the opening remarks from MassAITC Co-Principal Investigator, Niteesh Choudhry, MD, PhD and from Rose Li, PhD, MBA who leads the AITC Coordinating Center.